IJCM  Vol.7 No.5 , May 2016
Pro-Oxidant Antioxidant Balance in Inflammatory Bowel Disease
Abstract: Background: Inflammatory bowel disease (IBD) is associated with increased morbidity and incident of colon cancer; however its etiology is still unclear. Currently, one of the most probable pathogenesis patterns is increased permeability of bowel membrane and it seems that oxidative stress plays an important role in this pathway. This study was done to assess the pro-oxidant antioxidant balance (PAB) in these patients. Materials: This was a cross sectional study of 2 groups including 50 patients with diagnosed IBD and 50 healthy controls. Patients were selected purposively from those referring to adult gastroenterology clinic in 2013. SPSS (ver11.5) has been. A P value < 0.05 was regarded as statistically significant. Results: Mean PAB in patients and controls group was 119.98 ± 38.98 HK unite and 52.67 ± 22.80 HK unite, respectively, (P value < 0.001). PAB mean in ulcerative colitis patients was 120.60 ± 33.90 HK unite and in CD patients was 118.20 ± 45.99 HK unite, and showed no significant difference (P value = 0.85). PAB and MDA could detect healthy subjects from IBD patients with sensitivity more that 90% and specificity more than 84%. Conclusion: PAB shifted to pro-oxidants in IBD patients; moreover this shift was unrelated to disease type. These tests could use as screening test.
Cite this paper: Esmaelzadeh, A. , Vosooghinia, H. , Reza Sheikhian, M. , Hosseini, H. , Hamidi Alamdari, D. , Ahmadi, F. , Emadzadeh, M. and Pakdaman Shahri, S. (2016) Pro-Oxidant Antioxidant Balance in Inflammatory Bowel Disease. International Journal of Clinical Medicine, 7, 334-341. doi: 10.4236/ijcm.2016.75035.

[1]   Longo, D., Fauci, A., Kasper, D., Hauser, S., Jameson, J. and Loscalzo, J. (2011) Harrison’s Principles of Internal Medicine. McGraw Hill Professional.

[2]   Molodecky, N.A., Soon, I.S., Rabi, D.M., Ghali, W.A., Ferris, M., Chernoff, G., et al. (2012) Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases with Time, Based on Systematic Review. Gastroenterology, 142, 46-54.

[3]   Scarpa, M. and Stylianou, E. (2012) Epigenetics: Concepts and Relevance to IBD Pathogenesis. Inflammatory Bowel Diseases, 18, 1982-1996.

[4]   Glocker, E. and Grimbacher, B. (2012) Inflammatory Bowel Disease: Is It a Primary Immunodeficiency? Cellular and Molecular Life Sciences, 69, 41-48.

[5]   Hendrickson, B.A., Gokhale, R. and Cho, J.H. (2002) Clinical Aspects and Pathophysiology of Inflammatory Bowel Disease. Clinical Microbiology Reviews, 15, 79-94.

[6]   Khor, B., Gardet, A. and Xavier, R.J. (2011) Genetics and Pathogenesis of Inflammatory Bowel Disease. Nature, 474, 307-317.

[7]   Hollander, D., Vadheim, C.M., Brettholz, E., Petersen, G.M., Delahunty, T. and Rotter, J.I. (1986) Increased Intestinal Permeability in Patients with Crohn’s Disease and Their Relatives: A Possible Etiologic Factor. Annals of Internal Medicine, 105, 883-885.

[8]   Ukabam, S., Clamp, J. and Cooper, B. (1983) Abnormal Small Intestinal Permeability to Sugars in Patients with Crohn’s Disease of the Terminal Ileum and Colon. Digestion, 27, 70-74.

[9]   Hollander, D. (1988) Crohn’s Disease—A Permeability Disorder of the Tight Junction? Gut, 29, 1621-1624.

[10]   Halliwell, B. and Gutteridge, J. (1999) Oxygen Is a Toxic Gas: An Introduction to Oxygen Toxicity and Reactive Oxygen Species. Free Radicals in Biology and Medicine, 3, 1-35.

[11]   Aruoma, O.I., Kaur, H. and Halliwell, B. (1991) Oxygen Free Radicals and Human Diseases. The Journal of the Royal Society for the Promotion of Health, 111, 172-177.

[12]   Halliwell, B. and Gutteridge, J. (1985) Free Radicals in Biology and Medicine. Pergamon.

[13]   Harris, M.L., Schiller, H.J., Reilly, P.M., Donowitz, M., Grisham, M.B. and Bulkley, G.B. (1992) Free Radicals and Other Reactive Oxygen Metabolites in Inflammatory Bowel Disease: Cause, Consequence or Epiphenomenon? Pharmacology & Therapeutics, 53, 375-408.

[14]   Rezaie, A., Parker, R.D. and Abdollahi, M. (2007) Oxidative Stress and Pathogenesis of Inflammatory Bowel Disease: An Epiphenomenon or the Cause? Digestive Diseases and Sciences, 52, 2015-2021.

[15]   Lih-Brody, L., Powell, S.R., Collier, K.P., Reddy, G.M., Cerchia, R., Kahn, E., et al. (1996) Increased Oxidative Stress and Decreased Antioxidant Defenses in Mucosa of Inflammatory Bowel Disease. Digestive Diseases and Sciences, 41, 2078-2086.

[16]   Hoffenberg, E.J., Deutsch, J., Smith, S. and Sokol, R.J. (1997) Circulating Antioxidant Concentrations in Children with Inflammatory Bowel Disease. The American Journal of Clinical Nutrition, 65, 1482-1488.

[17]   Koutroubakis, I.E., Malliaraki, N., Dimoulios, P.D., Karmiris, K., Castanas, E. and Kouroumalis, E.A. (2004) Decreased Total and Corrected Antioxidant Capacity in Patients with Inflammatory Bowel Disease. Digestive Diseases and Sciences, 49, 1433-1437.

[18]   Ioannidis, O., Varnalidis, I., Paraskevas, G. and Botsios, D. (2011) Nutritional Modulation of the Inflammatory Bowel Response. Digestion, 84, 89-101.

[19]   D’Odorico, A., Bortolan, S., Cardin, R., D’Inca’, R., Martines, D., Ferronato, A. and Sturniolo, G.C. (2001) Reduced Plasma Antioxidant Concentrations and Increased Oxidative DNA Damage in Inflammatory Bowel Disease. Scandinavian Journal of Gastroenterology, 36, 1289-1294.

[20]   Achitei, D., Ciobica, A., Balan, G., Gologan, E., Stanciu, C. and Stefanescu, G. (2013) Different Profile of Peripheral Antioxidant Enzymes and Lipid Peroxidation in Active and Non-Active Inflammatory Bowel Disease Patients. Digestive Diseases and Sciences, 58, 1244-1249.

[21]   Hengstermann, S., Valentini, L., Schaper, L., Buning, C., Koernicke, T., Maritschnegg, M., et al. (2008) Altered Status of Antioxidant Vitamins and Fatty Acids in Patients with Inactive Inflammatory Bowel Disease. Clinical Nutrition, 27, 571-578.

[22]   Alamdari, D.H., Paletas, K., Pegiou, T., Sarigianni, M., Befani, C. and Koliakos, G. (2007) A Novel Assay for the Evaluation of the Prooxidant-Antioxidant Balance, before and after Antioxidant Vitamin Administration in Type II Diabetes Patients. Clinical Biochemistry, 40, 248-254.

[23]   Kruidenier, L., Kuiper, I., van Duijn, W., Mieremet-Ooms, M.A., van Hogezand, R.A., Lamers, C.B., et al. (2003) Imbalanced Secondary Mucosal Antioxidant Response in Inflammatory Bowel Disease. The Journal of Pathology, 201, 17-27.